Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten; Michel W J M Wouters; Doranne L Hilarius; John B Haanen; Christian U Blank; Maureen J B Aarts; Franchette W P J van den Berkmortel; Jan-Willem B de Groot; Geke A P Hospers; Ellen Kapiteijn; Djura Piersma; Roos S van Rijn; Karijn P M Suijkerbuijk; Willeke A M Blokx; Bert-Jan J Ten Tije; Astrid A M van der Veldt; Art Vreugdenhil; Marye J Boers-Sonderen; Alfonsus J M van den Eertwegh

doi:10.1038/s41416-021-01312-1

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Jesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, John B Haanen, Christian U Blank, Maureen J B Aarts, Franchette W P J van den Berkmortel, Jan-Willem B de Groot, Geke A P Hospers, Ellen Kapiteijn, Djura Piersma, Roos S van Rijn, Karijn P M Suijkerbuijk, Willeke A M Blokx, Bert-Jan J Ten Tije, Astrid A M van der Veldt, Art Vreugdenhil, Marye J Boers-Sonderen, Alfonsus J M van den Eertwegh^*

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Abstract

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1

Original language	English
Article number	1746
Number of pages	1
Journal	British Journal of Cancer
Volume	124
Issue number	10
DOIs	https://doi.org/10.1038/s41416-021-01312-1
Publication status	Published - 11 May 2021

Access to Document

10.1038/s41416-021-01312-1

1 Article

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis
van Breeschoten, J., Wouters, M. W. J. M., Hilarius, D. L., Haanen, J. B., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Blokx, W. A. M., ten Tije, B. J. J., van der Veldt, A. A. M., Vreugdenhil, A., Boers-Sonderen, M. J. & van den Eertwegh, A. J. M., 30 Mar 2021, In: British Journal of Cancer. 124, 7, p. 1222-1230 9 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access

Cite this

van Breeschoten, J., Wouters, M. W. J. M., Hilarius, D. L., Haanen, J. B., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J.-W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Blokx, W. A. M., Ten Tije, B.-J. J., van der Veldt, A. A. M., Vreugdenhil, A., Boers-Sonderen, M. J., & van den Eertwegh, A. J. M. (2021). Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. British Journal of Cancer, 124(10), Article 1746. https://doi.org/10.1038/s41416-021-01312-1

@article{cd906539c733470cbb16ad0fe41c81ba,

title = "Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis",

abstract = "A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1",

author = "{van Breeschoten}, Jesper and Wouters, {Michel W J M} and Hilarius, {Doranne L} and Haanen, {John B} and Blank, {Christian U} and Aarts, {Maureen J B} and {van den Berkmortel}, {Franchette W P J} and {de Groot}, {Jan-Willem B} and Hospers, {Geke A P} and Ellen Kapiteijn and Djura Piersma and {van Rijn}, {Roos S} and Suijkerbuijk, {Karijn P M} and Blokx, {Willeke A M} and {Ten Tije}, {Bert-Jan J} and {van der Veldt}, {Astrid A M} and Art Vreugdenhil and Boers-Sonderen, {Marye J} and {van den Eertwegh}, {Alfonsus J M}",

year = "2021",

month = may,

day = "11",

doi = "10.1038/s41416-021-01312-1",

language = "English",

volume = "124",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer",

number = "10",

}

van Breeschoten, J, Wouters, MWJM, Hilarius, DL, Haanen, JB, Blank, CU, Aarts, MJB, van den Berkmortel, FWPJ, de Groot, J-WB, Hospers, GAP, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, Blokx, WAM, Ten Tije, B-JJ, van der Veldt, AAM, Vreugdenhil, A, Boers-Sonderen, MJ & van den Eertwegh, AJM 2021, 'Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis', British Journal of Cancer, vol. 124, no. 10, 1746. https://doi.org/10.1038/s41416-021-01312-1

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. / van Breeschoten, Jesper; Wouters, Michel W J M; Hilarius, Doranne L et al.
In: British Journal of Cancer, Vol. 124, No. 10, 1746, 11.05.2021.

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

TY - JOUR

T1 - Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

AU - van Breeschoten, Jesper

AU - Wouters, Michel W J M

AU - Hilarius, Doranne L

AU - Haanen, John B

AU - Blank, Christian U

AU - Aarts, Maureen J B

AU - van den Berkmortel, Franchette W P J

AU - de Groot, Jan-Willem B

AU - Hospers, Geke A P

AU - Kapiteijn, Ellen

AU - Piersma, Djura

AU - van Rijn, Roos S

AU - Suijkerbuijk, Karijn P M

AU - Blokx, Willeke A M

AU - Ten Tije, Bert-Jan J

AU - van der Veldt, Astrid A M

AU - Vreugdenhil, Art

AU - Boers-Sonderen, Marye J

AU - van den Eertwegh, Alfonsus J M

PY - 2021/5/11

Y1 - 2021/5/11

N2 - A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1

AB - A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01312-1

U2 - 10.1038/s41416-021-01312-1

DO - 10.1038/s41416-021-01312-1

M3 - Erratum / corrigendum / retractions

C2 - 33723402

SN - 0007-0920

VL - 124

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 10

M1 - 1746

ER -

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Abstract

Access to Document

Fingerprint

Research output

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis

Cite this